Sofosbuvir/velpatasvir for chronic hepatitis C infection in patients with transfusion-dependent thalassemia

Am J Hematol. 2019 Feb;94(2):E43-E45. doi: 10.1002/ajh.25339. Epub 2018 Nov 29.

Authors

Ala I Sharara¹, Luma Basma O Rustom¹, Majd Marrache¹, Hussein H Rimmani¹, Halim Bou Daher¹, Suzanne Koussa², Ali Taher³

Affiliations

¹ Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
² The Chronic Care Center, Hazmieh, Lebanon.
³ Division of Hematology/Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

PMID: 30394575
DOI: 10.1002/ajh.25339

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Antiviral Agents / therapeutic use
Blood Transfusion
Carbamates / therapeutic use*
Female
Hepatitis C, Chronic / drug therapy*
Hepatitis C, Chronic / transmission
Heterocyclic Compounds, 4 or More Rings / therapeutic use*
Humans
Male
Sofosbuvir / therapeutic use*
Thalassemia / complications*
Thalassemia / therapy
Young Adult

Substances

Antiviral Agents
Carbamates
Heterocyclic Compounds, 4 or More Rings
velpatasvir
Sofosbuvir